Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) insider Caryn Parlavecchio sold 1,451 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $9.33, for a total value of $13,537.83. Following the completion of the transaction, the insider now owns 151,988 shares in the company, valued at approximately $1,418,048.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Scholar Rock Trading Up 0.9 %
Shares of NASDAQ SRRK traded up $0.08 during trading on Monday, hitting $9.40. 1,177,659 shares of the company were exchanged, compared to its average volume of 831,826. Scholar Rock Holding Co. has a 12-month low of $5.93 and a 12-month high of $21.17. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.04 and a current ratio of 6.04. The company has a fifty day moving average price of $8.74 and a 200-day moving average price of $12.39. The firm has a market capitalization of $752.28 million, a PE ratio of -4.50 and a beta of 0.85.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.01. During the same period in the previous year, the business posted ($0.47) EPS. As a group, equities research analysts expect that Scholar Rock Holding Co. will post -2.39 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on SRRK
Institutional Trading of Scholar Rock
Several institutional investors and hedge funds have recently bought and sold shares of SRRK. Price T Rowe Associates Inc. MD raised its holdings in Scholar Rock by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,321,471 shares of the company’s stock valued at $156,444,000 after buying an additional 1,149,519 shares during the period. Eventide Asset Management LLC purchased a new stake in Scholar Rock in the 4th quarter valued at about $18,287,000. Candriam S.C.A. purchased a new stake in Scholar Rock in the 2nd quarter valued at about $6,201,000. Millennium Management LLC raised its holdings in Scholar Rock by 159.2% in the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company’s stock valued at $7,710,000 after buying an additional 568,512 shares during the period. Finally, Marshall Wace LLP raised its holdings in Scholar Rock by 1,051.3% in the 2nd quarter. Marshall Wace LLP now owns 487,285 shares of the company’s stock valued at $4,059,000 after buying an additional 444,961 shares during the period. 91.08% of the stock is currently owned by hedge funds and other institutional investors.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Recommended Stories
- Five stocks we like better than Scholar Rock
- Transportation Stocks Investing
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What is Short Interest? How to Use It
- 2 Option Strategies to Maximize Profits in a Bear Market
- 3 Fintech Stocks With Good 2021 Prospects
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.